Gut microbiota: A bridge between depression and cardiovascular disease-A narrative review

Xingdou Mu , Lele Feng , Hong Li , Yang Sun
{"title":"Gut microbiota: A bridge between depression and cardiovascular disease-A narrative review","authors":"Xingdou Mu ,&nbsp;Lele Feng ,&nbsp;Hong Li ,&nbsp;Yang Sun","doi":"10.1016/j.microb.2025.100292","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Depression and cardiovascular disease (CVD) exhibit a bidirectional relationship, with individuals suffering from either condition facing elevated risks of comorbidity and mortality. Emerging evidence highlights the gut microbiota (GM) as a critical mediator in this interaction.</div></div><div><h3>Methods</h3><div>This narrative review synthesizes current research on the role of GM and its metabolites in linking depression and CVD.</div></div><div><h3>Results</h3><div>Dysbiosis of GM is consistently observed in both conditions, characterized by reduced microbial diversity, decreased abundance of beneficial bacteria (e.g., Faecalibacterium, Roseburia), and increased pro-inflammatory species (e.g., Enterobacteriaceae). Key microbial metabolites, including short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), and indole-3-propionic acid (IPA), influence neuroendocrine, immune, and metabolic pathways. For instance, SCFAs modulate neuroinflammation and endothelial function, while TMAO exacerbates atherosclerosis. Depression-associated GM alterations disrupt the gut-brain axis via the hypothalamic-pituitary-adrenal (HPA) axis and vagus nerve, whereas CVD-related dysbiosis promotes systemic inflammation and endothelial dysfunction. Shared mechanisms, such as NLRP3 inflammasome activation and bile acid metabolism dysregulation, further connect these diseases. Therapeutic strategies targeting GM probiotics, dietary interventions, fecal microbiota transplantation (FMT), and metabolite modulation may alleviate both conditions. However, challenges remain in addressing heterogeneity across studies, establishing causal relationships, and optimizing personalized interventions. Future research should integrate multi-omics approaches and longitudinal studies to unravel the gut-brain-heart axis, paving the way for precision therapies.</div></div><div><h3>Conclusions</h3><div>This review underscores GM’s pivotal role in depression and CVD comorbidity, offering novel insights for clinical management and interdisciplinary treatment strategies.</div></div>","PeriodicalId":101246,"journal":{"name":"The Microbe","volume":"7 ","pages":"Article 100292"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Microbe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950194625000603","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Depression and cardiovascular disease (CVD) exhibit a bidirectional relationship, with individuals suffering from either condition facing elevated risks of comorbidity and mortality. Emerging evidence highlights the gut microbiota (GM) as a critical mediator in this interaction.

Methods

This narrative review synthesizes current research on the role of GM and its metabolites in linking depression and CVD.

Results

Dysbiosis of GM is consistently observed in both conditions, characterized by reduced microbial diversity, decreased abundance of beneficial bacteria (e.g., Faecalibacterium, Roseburia), and increased pro-inflammatory species (e.g., Enterobacteriaceae). Key microbial metabolites, including short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), and indole-3-propionic acid (IPA), influence neuroendocrine, immune, and metabolic pathways. For instance, SCFAs modulate neuroinflammation and endothelial function, while TMAO exacerbates atherosclerosis. Depression-associated GM alterations disrupt the gut-brain axis via the hypothalamic-pituitary-adrenal (HPA) axis and vagus nerve, whereas CVD-related dysbiosis promotes systemic inflammation and endothelial dysfunction. Shared mechanisms, such as NLRP3 inflammasome activation and bile acid metabolism dysregulation, further connect these diseases. Therapeutic strategies targeting GM probiotics, dietary interventions, fecal microbiota transplantation (FMT), and metabolite modulation may alleviate both conditions. However, challenges remain in addressing heterogeneity across studies, establishing causal relationships, and optimizing personalized interventions. Future research should integrate multi-omics approaches and longitudinal studies to unravel the gut-brain-heart axis, paving the way for precision therapies.

Conclusions

This review underscores GM’s pivotal role in depression and CVD comorbidity, offering novel insights for clinical management and interdisciplinary treatment strategies.
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信